ATC code G: Genito-urinary system and sex hormones |
---|
|
ATCvet only |
|
Other ATC codes |
|
ATC code G Genito-urinary system and sex hormones is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3][4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QG.[5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System
| |
---|---|
gastrointestinal tract / metabolism (A) |
|
blood and blood forming organs (B) |
|
cardiovascular system (C) |
|
skin (D) |
|
genitourinary system (G) |
|
endocrine system (H) |
|
infections and infestations (J, P, QI) |
|
malignant disease (L01–L02) |
|
immune disease (L03–L04) |
|
muscles, bones, and joints (M) |
|
brain and nervous system (N) |
|
respiratory system (R) |
|
sensory organs (S) |
|
other ATC (V) |
|
|
| |||||||||
---|---|---|---|---|---|---|---|---|---|
Antibiotics |
| ||||||||
Arsenic compounds |
| ||||||||
Quinoline derivatives |
| ||||||||
Organic acids |
| ||||||||
Sulfonamides |
| ||||||||
Antifungals |
| ||||||||
Other |
|
| |||||
---|---|---|---|---|---|
Cervical ripening |
| ||||
Contraction induction |
| ||||
|
Birth control methods
| |||||||
---|---|---|---|---|---|---|---|
Related topics |
| ||||||
Long-acting reversible contraception (LARC) |
| ||||||
Sterilization |
| ||||||
Hormonal contraception |
| ||||||
Barrier Methods |
| ||||||
Emergency Contraception (Post-intercourse) |
| ||||||
Spermicides |
| ||||||
Behavioral |
| ||||||
Experimental |
|
Tocolytics/labor repressants (G02CA)
| |
---|---|
β2 adrenoreceptor agonists |
|
Oxytocin antagonists |
|
NSAIDs |
|
Calcium channel blockers |
|
Myosin inhibitors |
|
| |
---|---|
Prolactin inhibitors |
|
Anti-inflammatory products for vaginal administration |
|
| |||||||||
---|---|---|---|---|---|---|---|---|---|
Estrogens |
| ||||||||
Antiestrogens |
| ||||||||
|
| |||||
---|---|---|---|---|---|
Progestogens (and progestins) |
| ||||
Antiprogestogens |
| ||||
|
| |||||
---|---|---|---|---|---|
GnRH modulators (incl. analogues) |
| ||||
Gonadotropins |
| ||||
Others (indirect) |
| ||||
|
Urologicals, including antispasmodics (G04B)
| |
---|---|
Acidifiers |
|
Urinary antispasmodics (primarily antimuscarinics) |
|
Other urologicals |
|
| |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
For erectile dysfunction |
| ||||||||||||
For premature ejaculation |
| ||||||||||||
|
Drugs used in benign prostatic hyperplasia (G04C)
| |
---|---|
5α-Reductase inhibitors |
|
Alpha-1 blockers |
|
Steroidal antiandrogens |
|
Herbal products |
|
Others |
|